Numbers of SAEs according to treatment group
| SAE | Rituximab infusions | |
| Individually tailored (n=81) | Fixed-schedule (n=81) | |
| Number | 37 | 53 |
| Patients with SAE(s) | 26 | 31 |
| Infection | 18 | 18 |
| Pneumonia | 3 | 6 (1 died) |
| Bronchitis | 6 | 4 |
| Aspergillus fumigatus colonisation | 1 | 0 |
| Prostatitis | 2 | 0 |
| Septicaemia (from urinary tract) | 1 | 2 |
| Urinary infection | 0 | 1 |
| Septicaemia (fungal) | 1 | 0 |
| Cholecystitis | 1 | 0 |
| Ear, nose and throat | 0 | 1 |
| Sigmoid abscess | 0 | 1 |
| Colitis (Campylobacter sp.) | 1 | 0 |
| Others | 2 | 3 |
| Cancer | 1 | 2 |
| Thromboembolic events | 1 | 3 |
| Cardiac events | 4 | 7 |
| Pregnancy | 0 | 1 |
| Neutropaenia | 1 | 0 |
| Others | 11 | 22 |
SAEs, severe adverse events.